Drug Topics
JUNE 13, 2025
Researchers developed, pilot-tested, and evaluated the feasibility of a telehealth electronic application that simulated pharmacists’ prescribing of contraceptives to adolescents and young adults.
Pharmacy Times
JUNE 13, 2025
In two phase 3 clinical trials, enlicitide decanoate demonstrated clinically significant reductions in low-density lipoprotein cholesterol (LDL-C) in patients with hyperlipidemia and familial hypercholesterolemia.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Topics
JUNE 13, 2025
News FDA Updates Law and Advocacy Technology Trends Viewpoints All News Media In-Depth Insights Pharmacist View Script-Ed Expert Interviews Podcasts Conferences Conference Coverage Conference Listing Resources Disease Awareness White Board Video American Pharmacists Month Sponsored Resources CME/CE Partners Publications Drug Topics Journal Total Pharmacy Journal Submission of Articles Events Virtual Events Total Pharmacy Solutions Summit Business Business Strategies Patient Services Pharmacy Inv
Pharmaceutical Technology
JUNE 13, 2025
Skip to site menu Skip to page content Switch language: translate --> PT Menu Search Sections Home News Analysis Features Comment & Opinion Projects Data Insights Sectors Clinical Trials Drug Manufacturers Therapy Area Cardiovascular Central Nervous System Immunology Infectious Disease Oncology Respiratory Pricing and Market Access Themes Artificial Intelligence Corporate Governance Cloud Cybersecurity Environmental Sustainability Internet of Things Robotics Social Responsibility Covid-19 Insigh
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Drug Topics
JUNE 13, 2025
Polypharmacy and potentially inappropriate medications are cited as concerns in older adults who require long-term care, especially for those with comorbidities or at multiple institutions.
Pharma Marketing Network
JUNE 13, 2025
By Max Kopp Diabetes care is entering a new era—yet even in 2025, continuous glucose monitors (CGMs) remain out of reach for millions. Despite a decade of innovation, current CGMs often fail to meet the needs of everyday people with type 2 diabetes, particularly those in under-resourced or underserved communities. High costs, skin invasiveness, and insurance limitations act as real barriers, not just for adoption, but for long-term engagement.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Pharmacy Times
JUNE 13, 2025
Panelists discuss how pharmacists are essential in managing chronic graft-vs-host disease (cGVHD) by addressing challenges like toxicity, financial and logistical barriers, and a lack of awareness, while advocating for patient education, collaboration with health care teams, and ensuring access to necessary therapies.
Drug Topics
JUNE 13, 2025
News FDA Updates Law and Advocacy Technology Trends Viewpoints All News Media In-Depth Insights Pharmacist View Script-Ed Expert Interviews Podcasts Conferences Conference Coverage Conference Listing Resources Disease Awareness White Board Video American Pharmacists Month Sponsored Resources CME/CE Partners Publications Drug Topics Journal Total Pharmacy Journal Submission of Articles Events Virtual Events Total Pharmacy Solutions Summit Business Business Strategies Patient Services Pharmacy Inv
Pharmacy Times
JUNE 13, 2025
Panelists discuss how pharmacists improve patient outcomes in chronic graft-vs-host disease (cGVHD) by addressing accessibility and tolerability challenges, optimizing drug regimens, managing adherence, and fostering trust with patients to ensure consistent therapy and long-term success.
Drug Topics
JUNE 13, 2025
News FDA Updates Law and Advocacy Technology Trends Viewpoints All News Media In-Depth Insights Pharmacist View Script-Ed Expert Interviews Podcasts Conferences Conference Coverage Conference Listing Resources Disease Awareness White Board Video American Pharmacists Month Sponsored Resources CME/CE Partners Publications Drug Topics Journal Total Pharmacy Journal Submission of Articles Events Virtual Events Total Pharmacy Solutions Summit Business Business Strategies Patient Services Pharmacy Inv
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
pharmaphorum
JUNE 13, 2025
US Senators Bernie Sanders and Angus King have introduced a bill that seeks to ban direct-to-consumer (DTC) advertising by the pharma industry.
Pharmacy Times
JUNE 13, 2025
Ribociclib in combination with a nonsteroidal aromatase inhibitor (NSAI) improved invasive disease-free survival (iDFS) while allowing for better quality of life in hormone receptor-positive (HR+)/human epidermal growth receptor 2-negative (HER2−) early breast cancer.
Fierce Pharma
JUNE 13, 2025
Pfizer's CEO discussed the extensive due diligence the company has conducted on the 3SBio PD-1xVEGF deal. Otsuka detailed its phase 3 data in the kidney disease IgAN. Novartis is pressing for a speedy ruling in its Entresto patent litigation against MSN Pharmaceuticals.
Pharma Marketing Network
JUNE 13, 2025
Artificial intelligence is rapidly transforming industries, and the pharmaceutical sector is no exception. When it comes to marketing strategies , AI is reshaping how pharma companies reach healthcare professionals (HCPs), engage patients, and optimize campaign performance. But what exactly does this mean for pharma marketers in 2025? Are we merely adding tools to the toolkit—or rewriting the entire playbook?
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Pharmafile
JUNE 13, 2025
The Pharmaceutical Marketing (PM) Society has partnered with the Chartered Institute of Marketing (CIM) to launch the PMS & CIM Marketing Leaders Programme – a new initiative aimed at strengthening strategic capability and standards within pharma marketing. The programme will consist of a series of three-day, in-person training sessions delivered by senior CIM course directors […] The post PM Society and CIM launch new leadership programme for pharma marketers appeared first on Pharmaf
The Guardian - Pharmaceutical Industry
JUNE 13, 2025
AviadoBio’s breakthrough therapy hopes to stop progress of FTD, which is usually diagnosed in people under 65 Behind the gleaming glass facade of an office block in east London’s Docklands, Dr Martina Esposito Soccoio is pipetting ribonucleic acid into test tubes. Here, not far from Canary Wharf’s multinational banks, a British university spinout is working on a breakthrough treatment for a form of dementia that affects millions of people worldwide.
Fierce Pharma
JUNE 13, 2025
Merck & Co.’s Keytruda has become the first immunotherapy approved by the FDA to be used around surgery to treat resectable locally advanced head and neck cancer. But the indication is limited to PD-L1-positive disease.
European Pharmaceutical Review
JUNE 13, 2025
The Medicines and Healthcare Products regulatory agency (MHRA) has issued another Class 2 recall, bringing the total number of pharmaceutical products given this classification in the past month to three. The agency defines Class 2 as a major defect. While not life-threatening, recall action must be taken within 48 hours. Recall due to packaging error Inhixa The latest medicine to be given this classification ( drug alert number: EL(25)A/27 ) is the injectable solution Inhixa 12,000IU (120mg)/0
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Pharmacy Times
JUNE 13, 2025
The data from the 5-year analysis of arm C validate and support the efficacy and safety of zanabrutinib for treatment-naïve patients with CLL/SLL harboring del(17p).
Pharmafile
JUNE 13, 2025
EpiEndo Pharmaceuticals has announced the publication of three peer-reviewed articles in Pulmonary Pharmacology and Therapeutics, highlighting the therapeutic potential of its lead asset, EP395 (glasmacinal), as an oral treatment for chronic obstructive pulmonary disease (COPD). The published data includes findings from both clinical and preclinical studies.
PharmaShots
JUNE 13, 2025
Shots: The CVMP has recommended Zenrelia (ilunocitinib) for the treatment of pruritus linked to allergic dermatitis & clinical symptoms of atopic dermatitis in dogs Opinion was based on clinical data demonstrating quality, safety, efficacy, & a favorable benefit-risk profile incl. a non-inferiority study conducted as a part of the EU approval process Elanco plans to launch Zenrelia after marketing authorization, with supply available by Q3’25 end & anticipates additional approv
Fierce Pharma
JUNE 13, 2025
Zusduri is the first approved therapy for patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC), standing to replace the current surgical standard-of-care.
Pharmacy Times
JUNE 13, 2025
Pharmacists are redefining health care by bridging clinical and economic evidence, making a real difference in patient outcomes through health economics and outcomes research (HEOR).
pharmaphorum
JUNE 13, 2025
EVERSANA expands commercialisation portfolio with OS Therapies and Iterum Therapeutics partnerships Sara.
Pharmaceutical Commerce
JUNE 13, 2025
As the rising cost of prescription medications in the United States becomes an increasing barrier for millions of people, how can we effectively address and improve patient adherence?
Pharmafile
JUNE 13, 2025
Bristol Myers Squibb (BMS) has presented new data from its phase 3 POETYK PsA-1 trial, showing that Sotyktu (deucravacitinib) significantly improved symptoms in adults with active psoriatic arthritis (PsA) compared to placebo. Findings were shared at the 2025 European Alliance of Associations for Rheumatology (EULAR) Congress in Barcelona, Spain, taking place 11 to 14 June. […] The post Bristol Myers Squibb reports positive results for psoriatic arthritis treatment appeared first on Pharma
Pharmaceutical Commerce
JUNE 13, 2025
In the second part of her Pharma Commerce video interview, Kirsten Newquist, Identiv’s CEO, describes why this technology is essential for pharmaceutical safety and efficacy.
PharmaShots
JUNE 13, 2025
Shots: The P-II trial assessed barzolvolimab (Q4W: 75 or 150mg; Q8W: 300mg) vs PBO for 16wks. in 208 CSU pts unresponsive to antihistamines, followed by 36wks. of active treatment, where 75mg & PBO pts were re-randomized to 150 or 300mg; pts were then followed for 24wks. Enrolment to P-III ( EMBARQ-CSU1 & EMBARQ-CSU2 ) trials is ongoing Trial met its 1EP of significant mean UAS7 reduction at Wk. 12 across all doses, with rapid improvements by Wk. 1, sustained or deepened through Wk. 76
The Checkup by Singlecare
JUNE 13, 2025
Wellbutrin ( bupropion ) is an atypical antidepressant that is FDA approved to treat major depressive disorder and seasonal affective disorder. It’s also used to help people quit smoking. Some other medications contain bupropion with other active ingredients, including Contrave (bupropion and naltrexone) for weight loss and Auvelity (bupropion and dextromethorphan) for depression.
PharmaShots
JUNE 13, 2025
Shots: The CVMP has recommended Nobivac L6 & Nobivac LoVo L6 for the active immunization of dogs against leptospirosis; EC’s decision expected by Q3’25 The vaccine protects against 6 Leptospira serovars: Canicola, Copenhageni, Bratislava, Bananal/Lianguang, Icterohaemorrhagiae, & Grippotyphosa, preventing mortality, renal carriage, renal lesions, & urinary excretion while reducing infection & clinical signs Nobivac L6 is administered as 2 doses in dogs with an interval of 4wks.,
pharmaphorum
JUNE 13, 2025
Hopes rise for a new treatment option for people living with lupus, after UCB and Biogen reveal phase 3 data with their anti-CD40L antibody DZP
PharmaShots
JUNE 13, 2025
Shots: BioNTech has entered into a definitive purchase agreement to acquire CureVac in an all-stock transaction, strengthening its mRNA tech & capabilities As per the deal, each CureVac share will be exchanged for ~$5.46 in BioNTech ADSs, implying a total equity value of ~$1.25B, with a collar-adjusted exchange ratio (0.04318 if BioNTech’s 10-day VWAP >$126.55; 0.06476 if <$84.37), resulting in CureVac shareholders owning 4–6% of BioNTech; closing expected in 2025 CureVac will become a w
pharmaphorum
JUNE 13, 2025
AstraZeneca taps China's CSPC Pharma for new drug candidates a second time – and the latest AI-focused alliance is a big one.
Expert insights. Personalized for you.
470 
Let's personalize your content